Latest Research
All publications from the Cancer3.AI database, newest first.
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.
Fernandez J, et al
Researchers reviewed the role of epigenetic mutations in chronic myelomonocytic leukemia (CMML), a rare blood cancer that combines features of two distinct bone marrow disorders and frequently progresses to acute myeloid leukemia. The study focused on two major classes of epigenetic regulatory genes, examining how frequently mutations occur in these genes among CMML patients and how such mutations influence disease outcomes and survival. Key findings highlight that wider clinical use of genetic sequencing has revealed just how common these epigenetic mutations are, with mutations in genes such as ASXL1 and TET2 now incorporated into modern prognostic models used to predict patient outcomes. Importantly, a deeper understanding of how these mutations disrupt normal cellular regulation has begun to drive the development of targeted therapies tailored to specific genetic profiles. These advances offer clinicians a more precise roadmap for identifying which patients are most likely to respond to particular treatments, potentially improving care for a disease that has historically had limited therapeutic options.
Current hematologic malignancy reports
Source →Epigenetic risk stratification in juvenile myelomonocytic leukemia by targeted methylation analysis of the BMP4 locus.
Ghanjati F, et al
Researchers investigated whether DNA methylation at a specific gene called BMP4 could serve as a reliable biomarker for predicting outcomes in juvenile myelomonocytic leukemia (JMML), a rare and aggressive blood cancer affecting young children. Using a targeted sequencing technique called bisulfite next-generation sequencing, the team analyzed bone marrow samples from 111 children with JMML and found that BMP4 methylation levels varied widely across patients and correlated significantly with known clinical risk factors such as patient age and fetal hemoglobin levels. Children with the highest BMP4 methylation had a five-year disease-free survival rate of only 38%, compared to 62% for those with the lowest methylation levels, a statistically significant difference that underscores the prognostic value of this marker. The BMP4 methylation test also showed good agreement with more comprehensive genome-wide methylation profiling, suggesting it can capture similar risk information at a fraction of the cost and complexity. These findings position targeted BMP4 methylation analysis as a practical, complementary tool that clinicians could use alongside existing genetic tests to better stratify JMML patients by risk and guide treatment decisions.
Clinical epigenetics
Source →Pericardial fluid cytology as a diagnostic tool for diffuse large B-cell lymphoma: a case report.
Sierra-Rivera A, et al
A new case report published in Advances in Laboratory Medicine documents a rare diagnosis of primary cardiac lymphoma — specifically diffuse large B-cell lymphoma (DLBCL) — in a woman presenting with breathing difficulties, chest pain, fatigue, cough, and pain on swallowing. Primary cardiac lymphoma is an exceptionally uncommon form of extranodal non-Hodgkin lymphoma, making its accurate and timely diagnosis a significant clinical challenge. In this case, the diagnosis was established through cytological analysis of pericardial fluid — the fluid surrounding the heart — combined with imaging techniques, avoiding the need for a more invasive endomyocardial biopsy. The patient successfully completed all planned chemotherapy cycles and is currently in remission. This case underscores the critical value of skilled cytological evaluation by laboratory professionals in detecting rare malignancies at an early stage. The findings suggest that pericardial fluid cytology can serve as a minimally invasive yet highly informative diagnostic approach for cardiac lymphomas.
Advances in laboratory medicine
Source →[Efficacy and Prognostic Evaluation of Hypomethylating Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasms].
Sun J, et al
Researchers at the Affiliated Hospital of Xuzhou Medical University evaluated the effectiveness and survival outcomes of hypomethylating agents (HMAs) — specifically decitabine and azacitidine — in 35 patients diagnosed with myelodysplastic/myeloproliferative neoplasms (MDS/MPN) between 2018 and 2024. The overall response rate across all patients was 51.4%, but decitabine demonstrated a significantly higher response rate (73.3%) compared to azacitidine (35.0%), making it the more effective treatment option in this cohort. The median overall survival for the entire group was 12 months and median progression-free survival was 10 months, with patients who completed four or more treatment courses and responded to therapy achieving longer survival. Multivariate analysis identified treatment regimen and platelet count as independent factors influencing treatment response, while the number of courses and treatment efficacy independently affected overall survival. Decitabine was also better tolerated in terms of gastrointestinal side effects, with azacitidine patients experiencing significantly more such reactions. These findings provide clinicians with practical guidance for selecting HMA therapy in MDS/MPN patients, suggesting decitabine may offer both superior efficacy and a more favorable tolerability profile.
Zhongguo shi yan xue ye xue za zhi
Source →A Rare Presentation of Bilateral Pheochromocytoma With a Flank Pain Radiating to the Back: A Case Report and Narrative Review.
Nadeem N, et al
Researchers report the case of a 32-year-old woman diagnosed with bilateral pheochromocytoma — a rare tumor of the adrenal glands that produces stress hormones — who presented with an unusual symptom profile of flank pain radiating to the back, without the classic signs of high blood pressure or episodic headaches. Imaging revealed tumors in both adrenal glands, and blood tests showed markedly elevated levels of plasma metanephrines, confirming the diagnosis despite normal urinary catecholamine results. The patient underwent successful surgical removal of both adrenal glands using a combination of robotic and open techniques, and was discharged on steroid replacement therapy with no evidence of disease recurrence. This case underscores that pheochromocytoma can present in atypical ways that may delay diagnosis, particularly when hypertension and classic symptoms are absent. Clinicians are advised to consider this diagnosis in patients with unexplained persistent flank pain and to prioritize early imaging alongside plasma metanephrine testing for timely and accurate detection.
AACE endocrinology and diabetes
Source →